Charles Reay Mackay joins Pfizer
This article was originally published in Scrip
Executive Summary
Pfizer has named Charles Reay Mackay chief scientific officer for its inflammation and immunology research unit. Professor Mackay will report directly to José-Carlos Gutiérrez-Ramos, group vice-president of BioTherapeutics R&D, and will be based in Pfizer's R&D hub in Cambridge, Massachusetts. Professor Mackay will join Pfizer from Monash University in Australia, where he is a research fellow, and the Charles Perkins Center within the Faculty of Medicine at Sydney University, where he was chair of diabetes. Inflammation and immunology is one of Pfizer's key therapeutic areas.
You may also be interested in...
Finding Value Left On The Shelf: Karuna Case Study
PureTech’s gamble to take an older Eli Lilly drug off the shelf to redevelop in a new indication paid off. The company aims to replicate this 'Karuna model' in the near future.
Podcast: NodThera On The Role Of The Brain In Driving Chronic Disease
Alan Watt, CEO of NodThera, a clinical-stage biotech developing brain-penetrant NLRP3 inflammasome inhibitors to treat chronic inflammatory diseases, talks to In Vivo about the company’s pipeline and recent data publication in the field of obesity.
Deals Of The Year 2023 Winners Revealed
For In Vivo's 16th annual Deals of the Year contest, we selected 12 nominees in three categories – Top Alliance, Top Financing and Top M&A. The polls are closed, and it is time to reveal the winners.